Browse

Conditionally replicating adenovirus improves gene replication efficiency and anticancer effect of E1-deleted adenovirus carrying TRAIL in head and neck squamous cell carcinoma

DC Field Value Language
dc.contributor.authorShim, Seon-Hui-
dc.contributor.authorLee, Choon-Taek-
dc.contributor.authorHah, J. Hun-
dc.contributor.authorLee, Jae-Jung-
dc.contributor.authorHeo, Dae Seog-
dc.contributor.authorSung, Myung-Whun-
dc.contributor.authorPark, Seok-Woo-
dc.date.accessioned2012-07-04T08:50:37Z-
dc.date.available2012-07-04T08:50:37Z-
dc.date.issued2010-02-
dc.identifier.citationCANCER SCIENCE; Vol.101 2; 482-487ko_KR
dc.identifier.issn1347-9032-
dc.identifier.urihttps://hdl.handle.net/10371/78491-
dc.description.abstractTo overcome the low efficiency of gene therapy, we combined a conditionally replicating adenovirus (CRAd) and an adenoviral vector with a therapeutic gene. CRAd has an oncolytic activity in cancer cells with abnormal Rb activity and helps the replication of therapeutic genes incorporated in the E1-deleted adenovirus. We investigated the anticancer effect of a combination of CRAd and adenovirus carrying tumor necrosis factor-related apoptosis inducing ligand (ad-TRAIL). We expected to see increased gene expression in cancer cells as well as an antitumor effect. With the combined application of CRAd and ad-luciferase in head and neck cancer cell lines, we observed considerably increased luciferase activity that was 10- to 50-fold greater than with ad-luciferase alone. The combination of CRAd and ad-TRAIL showed significant suppression of growth in cell lines and increased the sub-G1 portion of cells 30-fold compared to any single treatment. The expression of TRAIL was highly amplified by the combined treatment and was accompanied by expression of molecules related to apoptosis. In a xenograft animal model, mice treated with CRAd and ad-TRAIL showed complete regression of established tumors, whereas mice treated with CRAd or ad-TRAIL alone did not. In conclusion, this combined strategy using CRAd and adenovirus carrying a therapeutic gene increased the gene transfer rate and enhanced antitumor effects. We expect that this combination strategy could be extended to a multitarget cancer gene therapy by combining multiple adenoviruses and CRAd. (Cancer Sci 2010; 101: 482-487)ko_KR
dc.language.isoenko_KR
dc.publisherWILEY-BLACKWELL PUBLISHING, INCko_KR
dc.titleConditionally replicating adenovirus improves gene replication efficiency and anticancer effect of E1-deleted adenovirus carrying TRAIL in head and neck squamous cell carcinomako_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor심선휘-
dc.contributor.AlternativeAuthor이춘택-
dc.contributor.AlternativeAuthor이재정-
dc.contributor.AlternativeAuthor박석우-
dc.contributor.AlternativeAuthor허대석-
dc.contributor.AlternativeAuthor성명훈-
dc.identifier.doi10.1111/j.1349-7006.2009.01409.x-
dc.citation.journaltitleCANCER SCIENCE-
dc.description.citedreferenceRen XW, 2006, CANCER GENE THER, V13, P159, DOI 10.1038/sj.cgt.7700868-
dc.description.citedreferenceLee CT, 2006, CANCER RES, V66, P372, DOI 10.1158/0008-5272.CAN-05-1515-
dc.description.citedreferenceZhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792-
dc.description.citedreferenceLee CT, 2004, CANCER RES, V64, P6660-
dc.description.citedreferenceGeoerger B, 2004, CANCER RES, V64, P5753-
dc.description.citedreferenceDavydova J, 2004, CANCER RES, V64, P4319-
dc.description.citedreferenceKanerva A, 2004, GENE THER, V11, P552, DOI 10.1038/sj.gt.3302181-
dc.description.citedreferenceHuang Q, 2004, CLIN CANCER RES, V10, P1439-
dc.description.citedreferenceJang SH, 2004, INT J MOL MED, V13, P181-
dc.description.citedreferenceHuang TG, 2003, GENE THER, V10, P1241, DOI 10.1038/sj.gt.3301987-
dc.description.citedreferenceSeol JY, 2003, CANCER GENE THER, V10, P540, DOI 10.1038/sj.cgt.7700597-
dc.description.citedreferenceHermiston TW, 2002, CANCER GENE THER, V9, P1022, DOI 10.1038/sj.cgt.7700542-
dc.description.citedreferenceNanda D, 2001, CANCER RES, V61, P8743-
dc.description.citedreferenceHawkins LK, 2001, GENE THER, V8, P1123-
dc.description.citedreferenceHawkins LK, 2001, GENE THER, V8, P1142-
dc.description.citedreferenceHawkins LK, 2001, GENE THER, V8, P1132-
dc.description.citedreferenceSuzuki K, 2001, CLIN CANCER RES, V7, P120-
dc.description.citedreferenceKirn D, 2000, ONCOGENE, V19, P6660-
dc.description.citedreferenceEggert A, 2000, MED PEDIATR ONCOL, V35, P603-
dc.description.citedreferenceHeise C, 2000, NAT MED, V6, P1134-
dc.description.citedreferenceOzoren N, 2000, INT J ONCOL, V16, P917-
dc.description.citedreferenceKim KH, 2000, CLIN CANCER RES, V6, P335-
dc.description.citedreferenceLeverkus M, 2000, CANCER RES, V60, P553-
dc.description.citedreferenceLee SH, 1999, CANCER RES, V59, P5683-
dc.description.citedreferenceWildner O, 1999, CANCER RES, V59, P410-
dc.description.citedreferenceGriffith TS, 1998, CURR OPIN IMMUNOL, V10, P559-
dc.description.citedreferenceGriffith TS, 1998, J IMMUNOL, V161, P2833-
dc.description.citedreferenceHeise C, 1997, NAT MED, V3, P639-
dc.description.citedreferenceWiley SR, 1995, IMMUNITY, V3, P673-
dc.description.tc3-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Otorhinolaryngology (이비인후과학전공)Journal Papers (저널논문_이비인후과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse